Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00875524
Other study ID # CYD22
Secondary ID 2014-001709-41
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2009
Est. completion date December 2014

Study information

Verified date March 2022
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial evaluated the use of a tetravalent vaccine against dengue. Primary objectives: - To describe the humoral immune response to dengue before and after each vaccination with tetravalent dengue vaccine in adults, adolescents, and children. - To evaluate the safety of each vaccination with tetravalent dengue vaccine in the 4 age cohorts. - To evaluate the persistence of antibodies against dengue during 5 years after the first vaccination with tetravalent dengue vaccine in the 4 age cohorts.


Description:

Safety assessments included solicited reactions within 7 or 14 days after each injection, unsolicited adverse events within 28 days after each injection, and serious adverse events during the study period.


Recruitment information / eligibility

Status Completed
Enrollment 180
Est. completion date December 2014
Est. primary completion date August 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Years to 45 Years
Eligibility Inclusion Criteria : - Aged 2 to 45 years on the day of inclusion. - Provision of Informed Consent/Assent Form signed by the participant (and/or by the parent or another legally acceptable representative for participants <18 years). - Participant (and parent/guardian for participants <18 years) able to attend all scheduled visits and to comply with all trial procedures. - For a female participant of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to the first vaccination, until at least 4 weeks after the last vaccination. - Participant in good health, based on medical history, physical examination and laboratory parameters. Exclusion Criteria : - Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia. - For a female participant of child-bearing potential, known pregnancy or positive serum pregnancy test at Screening. - For a female participant of child-bearing potential, known pregnancy or positive urine pregnancy test on the day of the first injection. - Breast-feeding female participant. - Receipt of any vaccine in the 4 weeks preceding the first trial vaccination. - Human immunodeficiency virus, hepatitis B, or hepatitis C seropositivity in the blood sample taken at screening. - Planned participation in another clinical trial during the first year of the study. - Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the past 6 months, or long-term systemic corticosteroids therapy. - Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccines or to a vaccine containing any of the same substances. - Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator. - Current alcohol abuse or drug addiction that may interfere with the participant's ability to comply with trial procedures. - Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of immune response. - Participant deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent. - Laboratory abnormalities of at least moderate severity or clinically significant according to the Investigator in blood sample taken at screening. - Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination. - Planned receipt of any vaccine in the 4 weeks following the first trial vaccination. - Familial atopy medical history (parents, brothers, or sisters). - Previous vaccination with meningococcal A+C or typhoid vaccines within 3 years prior to inclusion. - History of meningococcal or typhoid infections (confirmed either clinically, serologically or microbiologically).

Study Design


Intervention

Biological:
CYD dengue vaccine serotypes (1, 2, 3, 4).
0.5 mL, Subcutaneous
Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide
Each at 0.5 mL, Subcutaneous, respectively

Locations

Country Name City State
Vietnam Sanofi Pasteur Investigational Site Long Xuyên An Giang Province

Sponsors (1)

Lead Sponsor Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype of the Parental Dengue Virus Strain Before and Following Injection (Inj.) With CYD Dengue Tetravalent Vaccine Geometric mean titers against each serotype of the parental dengue virus strains were assessed using the dengue Plaque Reduction Neutralization Test (PRNT). Pre-Inj. 1, 2, and 3 and 28 days Post-Inj. 1, 2, and 3
Primary Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype of the Parental Dengue Virus Strain During the Follow-up Period GMT against each serotype of the parental dengue virus strains were assessed using the dengue PRNT. Year 1, Year 2, Year 3 and Year 4 after the Third Injection
Primary Percentage of Participants With Antibody Titers >= 10 (1/Dil) Against Each Serotypes of the Parental Dengue Virus Strains Following Inj. With CYD Dengue Tetravalent Vaccine Antibody titer levels against each serotype of the parental dengue virus strains were assessed using the PRNT. Pre-Inj. 1, 2, and 3 and 28 days Post-Inj. 1, 2, and 3
Primary Percentage of Participants With Antibody Titers >= 10 (1/Dil) Against Each Serotypes of the Parental Dengue Virus Strains Following Inj. With CYD Dengue Tetravalent Vaccine During the Follow-up Period Antibody titer levels against each serotype of the parental dengue virus strains were assessed using the PRNT. Year 1, Year 2, Year 3 and Year 4 after the Third Injection
Primary Percentage of Participants With Solicited Inj. Site Reactions Following Any and Each Inj. With CYD Dengue Tetravalent Vaccine Solicited Inj. site reactions: Pain, Erythema, and Swelling. Pain:- Grade 1: easily tolerated, Grade 2: sufficiently discomforting to interfere with normal behavior or activities, Grade 3: Incapacitating, unable to perform usual activities. Erythema and Swelling:- Grade 1: <2.5 cm, Grade 2: >=2.5 to <5 cm, Grade 3: >= 5 cm. 7 days post-each injection
Primary Percentage of Participants With Solicited Systemic Reactions Following Any and Each Inj. With CYD Dengue Tetravalent Vaccine Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Fever:- Grade 1: >=37.5 degree Celsius (°C) to <=38.0°C, Grade 2: >38.0°C to <=39.0°C, Grade 3: >39.0°C. Headache, malaise, myalgia and asthenia: Grade 1: noticeable but does not interfere with daily activities, Grade 2: interferes with daily activities, Grade 3: prevents daily activities. 14 days post-each injection
See also
  Status Clinical Trial Phase
Recruiting NCT04514107 - A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue) N/A
Completed NCT00788151 - Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Phase 2
Completed NCT02510638 - The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia N/A
Completed NCT01666652 - A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults Phase 1
Completed NCT01477671 - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children N/A
Completed NCT01443247 - Role of Andi-d in Dengue Fever: a Pilot Study N/A
Completed NCT00831012 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults Phase 1
Completed NCT00089908 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults Phase 1
Completed NCT01983553 - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed NCT01134263 - Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Phase 3
Completed NCT02741128 - Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Phase 2
Completed NCT03620487 - Detection of Dengue Virus in Plasma of Patients in Nepal
Recruiting NCT02608047 - Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou N/A
Completed NCT02510690 - Factors Associated With Poor Dengue Outcomes in Malaysia N/A
Completed NCT01550016 - International Research Consortium on Dengue Risk Assessment, Management, and Surveillance N/A
Completed NCT01421732 - Laboratory Diagnosis and Prognosis of Severe Dengue N/A
Completed NCT00993447 - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Phase 2
Completed NCT01224639 - Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever Phase 1
Completed NCT01943825 - Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Phase 2
Active, not recruiting NCT03465254 - Dengue Serostatus Study in the Philippines